Bristol-Myers Squibb (id:8499 BMY)
57.55 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/23/2024 2:15:02 PM)
Exchange open, closes in 1 hour 44 minutes
About Bristol-Myers Squibb
Market Capitalization 115.11B
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
| Headquarters (address) |
Route 206 & Province Line Road Princeton 08543 NJ United States |
| Phone | 609 252 4621 |
| Website | https://www.bms.com |
| Employees | 34K |
| Sector | Healthcare |
| Industry | Drug Manufacturers General |
| Ticker | BMY |
| Exchange | New York Stock Exchange |
| Currency | USD |
| 52 week range | 39.35 - 61.08 |
| Market Capitalization | 115.11B |
| Dividend yield forward | 4.19 % |
| Dividend yield forward United States (ID:6, base:1858) | 4.48 % |
| P/E trailing | 11.54 |
| P/E forward | 8.07 |
| Price/Sale | 2.43 |
| Price/Book | 6.71 |
| Beta | 3.00 |
| EPS | -3.58 |
| EPS United States (ID:6, base:3382) | 24.33 |
Dividend growth streak
Bristol-Myers Squibb has raised their dividend 9.00 years in a row. This is above the 4.499729 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Bristol-Myers Squibb has raised their dividend 4.19 years in a row. This is below the 42121.954600 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Bristol-Myers Squibb has raised their dividend 7.34 years in a row. This is below the 12.560500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: Bristol-Myers Squibb has raised their dividend 4.92 years in a row. This is below the 10.207200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Bristol-Myers Squibb has raised their dividend 59.84 years in a row. This is below the 148.467900 year average in the 'Drug Manufacturers General' industry
Self funded year
Bristol-Myers Squibb years needed to self fund. This is below the 34.112811 year average in the 'Drug Manufacturers General' industry
Dividend growth streak
Bristol-Myers Squibb has raised their dividend 9.00 years in a row. This is above the 4.499729 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Bristol-Myers Squibb has raised their dividend 4.19 years in a row. This is below the 42121.954600 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Bristol-Myers Squibb has raised their dividend 7.34 years in a row. This is below the 12.560500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: Bristol-Myers Squibb has raised their dividend 4.92 years in a row. This is below the 10.207200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Bristol-Myers Squibb has raised their dividend 59.84 years in a row. This is below the 148.467900 year average in the 'Drug Manufacturers General' industry
Self funded year
Bristol-Myers Squibb years needed to self fund. This is below the 34.112811 year average in the 'Drug Manufacturers General' industry